PharmaCyte Biotech (PMCB) Competitors $1.81 -0.06 (-3.21%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends PMCB vs. OSTX, MURA, DTIL, KZR, THTX, KRON, VHAQ, BRNS, SYRS, and SCYXShould you be buying PharmaCyte Biotech stock or one of its competitors? The main competitors of PharmaCyte Biotech include OS Therapies (OSTX), Mural Oncology (MURA), Precision BioSciences (DTIL), Kezar Life Sciences (KZR), Theratechnologies (THTX), Kronos Bio (KRON), Viveon Health Acquisition (VHAQ), Barinthus Biotherapeutics (BRNS), Syros Pharmaceuticals (SYRS), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. PharmaCyte Biotech vs. OS Therapies Mural Oncology Precision BioSciences Kezar Life Sciences Theratechnologies Kronos Bio Viveon Health Acquisition Barinthus Biotherapeutics Syros Pharmaceuticals SCYNEXIS PharmaCyte Biotech (NASDAQ:PMCB) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation. Is PMCB or OSTX more profitable? PharmaCyte Biotech's return on equity of 1.38% beat OS Therapies' return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 1.38% 0.71% OS Therapies N/A N/A N/A Do analysts recommend PMCB or OSTX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AOS Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00 Does the media prefer PMCB or OSTX? In the previous week, OS Therapies had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 2 mentions for OS Therapies and 1 mentions for PharmaCyte Biotech. PharmaCyte Biotech's average media sentiment score of 0.93 beat OS Therapies' score of 0.09 indicating that PharmaCyte Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PharmaCyte Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OS Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of PMCB or OSTX? 34.2% of PharmaCyte Biotech shares are owned by institutional investors. 7.3% of PharmaCyte Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, PMCB or OSTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.662.74OS TherapiesN/AN/A-$7.79MN/AN/A Does the MarketBeat Community favor PMCB or OSTX? OS Therapies received 2 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/AOS TherapiesOutperform Votes2100.00% Underperform VotesNo Votes SummaryPharmaCyte Biotech beats OS Therapies on 6 of the 9 factors compared between the two stocks. Ad Weiss RatingsProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricPharmaCyte BiotechBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.90M$3.16B$5.36B$8.41BDividend YieldN/A1.77%5.22%4.20%P/E Ratio2.7416.48131.9317.57Price / SalesN/A343.231,440.1578.36Price / CashN/A139.6939.0633.56Price / Book0.553.904.744.57Net Income$330,000.00-$40.42M$115.43M$225.42M7 Day Performance1.12%-0.16%-0.86%-0.61%1 Month Performance-5.24%3.45%3.61%1.50%1 Year Performance-14.62%32.76%38.90%32.94% PharmaCyte Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBPharmaCyte Biotech1.466 of 5 stars$1.81-3.2%N/A-10.5%$13.90MN/A2.742Gap DownOSTXOS TherapiesN/A$2.92-2.3%N/AN/A$60.15MN/A0.00N/ANews CoverageGap UpMURAMural Oncology3.5844 of 5 stars$3.49+1.2%$16.00+358.5%N/A$59.07MN/A-0.34119Short Interest ↓DTILPrecision BioSciences4.1086 of 5 stars$8.48-0.8%$39.50+365.8%-13.1%$58.73M$87.64M40.79200Upcoming EarningsKZRKezar Life Sciences4.0289 of 5 stars$0.80flat$4.50+461.2%+7.9%$58.37M$7M-0.5960Stock SplitGap DownTHTXTheratechnologiesN/A$1.25-2.3%N/A+35.9%$57.48M$84.32M-12.50140KRONKronos Bio3.4089 of 5 stars$0.95flat$4.13+333.8%+10.6%$57.15M$8.41M-0.55100Short Interest ↓Gap UpVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$56.60MN/A0.002High Trading VolumeBRNSBarinthus Biotherapeutics3.5336 of 5 stars$1.43+4.4%$5.83+307.9%N/A$56.37M$800,000.00-0.87107Short Interest ↓News CoveragePositive NewsGap UpSYRSSyros Pharmaceuticals4.5145 of 5 stars$2.07-8.0%$5.00+141.5%+0.4%$55.33M$4.15M-0.48120High Trading VolumeSCYXSCYNEXIS1.4035 of 5 stars$1.45-2.7%N/A-22.0%$54.90M$140.14M-2.0160Positive News Related Companies and Tools Related Companies OSTX Competitors MURA Competitors DTIL Competitors KZR Competitors THTX Competitors KRON Competitors VHAQ Competitors BRNS Competitors SYRS Competitors SCYX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PMCB) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PMCB Stock Alerts